4.6 Review

CCR5: From Natural Resistance to a New Anti-HIV Strategy

Journal

VIRUSES-BASEL
Volume 2, Issue 2, Pages 574-600

Publisher

MDPI
DOI: 10.3390/v2020574

Keywords

CCR5; HIV; vaccine

Categories

Funding

  1. European Commission [201433]
  2. NIH [1 U19 AI062150]
  3. Bill and Melinda Gates Foundation [53030, PP1008144]

Ask authors/readers for more resources

The C-C chemokine receptor type 5 (CCR5) is a key player in HIV infection due to its major involvement in the infection process. Investigations into the role of the CCR5 coreceptor first focused on its binding to the virus and the molecular mechanisms leading to the entry and spread of HIV. The identification of naturally occurring CCR5 mutations has allowed scientists to address the CCR5 molecule as a promising target to prevent or limit HIV infection in vivo. Naturally occurring CCR5-specific antibodies have been found in exposed but uninfected people, and in a subset of HIV seropositive people who show long-term control of the infection. This suggests that natural autoimmunity to the CCR5 coreceptor exists and may play a role in HIV control. Such natural immunity has prompted strategies aimed at achieving anti-HIV humoral responses through CCR5 targeting, which will be described here.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available